|Podcasts|April 25, 2019
Episode 30: Challenges in Renal Disease Drug Development
Author(s)Lisa Henderson, Christen Harm
Pharm Exec editors interview Anna Sundgren, the renal disease strategy leader, Global Medicines Development at AstraZeneca, about the current CVRM landscape, challenges to renal drug development, and new therapeutics for chronic kidney disease.
Advertisement
Pharm Exec editors interview Anna Sundgren, the renal disease strategy leader, Global Medicines Development at AstraZeneca, about the current CVRM landscape, challenges to renal drug development, and new therapeutics for chronic kidney disease. This podcast was brought to you by
You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
How Exposed is The U.S. Pharmaceutical Supply Chain to China’s Updated Export Control Regulations?
2
Staying Ahead of Viral Evolution: Q&A with Robert Allen, Ph.D
3
Bristol Myers Squibb Expands Collaboration with Nvidia to Build AI Factory
4
Pharmaceutical Executive Daily: Bristol Myers Squibb Expands Partnership with Nvidia
5